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THE EVOLUTION OF HYPERTHERMIC INTRAPERITONEAL 
CHEMOTHERAPY IN THE SETTING OF ADVANCED OVARIAN CANCER  
 
KEVIN J. QUINDLEN 
 
ABSTRACT 
 
 Ovarian cancer is the second most common, and first most lethal 
gynecological cancer. It will affect one in seventy-eight women, and is commonly 
diagnosed in the later stages of the disease. The majority of the cancer’s lifespan is 
spent within the peritoneal cavity. Hyperthermic intraperitoneal chemotherapy 
(HIPEC) is an innovative new treatment that has been proven as an effective 
treatment in other peritoneal cancers. There is strong scientific evidence to support 
HIPEC as an ideal treatment for advanced ovarian cancer. Over the past two 
decades, there has been an increase in the number of studies focused on the efficacy 
of HIPEC with regards to advanced ovarian cancer. These studies have shown great 
promise, with two very recent phase III studies showing resounding results. It is 
also clear that there is a need for standardization throughout these scientific studies 
in order to reasonably introduce HIPEC as a standard of treatment.  
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INTRODUCTION 
 
 Cancer remains one of the greatest health risks within the United States, and 
throughout the world. According to the American Cancer Society, one in four deaths in 
the United States is due to cancer.1 Among the large variety of cancers, gynecological 
cancers are historically fairly common and often have a high mortality rate. 
Gynecological malignancies include all cancers that stem from the cells of the female 
reproductive system. While uterine cancer remains more common, ovarian cancer is the 
leading cause of gynecological cancer-related death, and the fifth leading cause of 
cancer-related death in females.1 According to recent statistical analysis done by the 
American Cancer Society, ovarian cancer accounts of 2.5% of all female malignancies 
and lead to 5% of female cancer-related deaths. Furthermore, the lifetime risk of ovarian 
cancer is 1.3%, or one in every seventy-eight women.2 The increased number of deaths 
found with ovarian cancer is attributed to the late diagnosis with most ovarian 
malignancies, which seem to lack of noticeable symptoms until the disease has reached 
the later stages of development.2 The symptoms of even later stage disease include pelvic 
or abdominal pain, bloating, indigestion, abdominal distention, early satiety, and pain 
with intercourse.3 These symptoms, especially considering these will not all be 
experienced at the same time or some even at all, are fairly nonspecific and could point to 
many, less serious health issues before arriving at advanced ovarian cancer. This poses a 
significant risk, as it leads to very late diagnosis and a much more difficult disease to 
treat (Figure 1). It was estimated that in 2018 there were 22,240 new cases of ovarian 
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cancer, which was accompanied by 14,070 ovarian cancer-related deaths.2,4 There are 
various types of ovarian cancer, from extremely rare to much more common. Epithelial 
ovarian carcinoma is the most common form of the disease, and therefore has the highest 
mortality rates. 
 
Figure 1: Cancer Staging. Average stage of diagnosis is Stage 3, which includes 
metastasis to other parts of the abdomen. 
Source: Deepam Medi Tours5 
 
Epithelial ovarian carcinoma (EOC) accounts for 90% of all ovarian cancers.2 
With EOC being the most common form of the disease, most studies focus on this 
histological subtype when determining treatment modalities, which is why this paper will 
also focus mainly on this specific histology. To further the issue of late stage diagnosis, 
65% of all EOC are diagnosed at either stage III or IV (Figure 2). Additionally, the most 
common subtype of EOC, serous carcinoma (52% of all EOCs), has a concerning 80% of 
all cases being diagnosed at stage III or IV.2 These data are represented graphically in 
Figure 2. While studies do exist for the treatment of rarer ovarian malignancies, 
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hyperthermic intraperitoneal chemotherapy (HIPEC) has only been implemented in the 
case of EOC, which will be the focus of this paper.  
 
 
Figure 2: American Joint Committee on Cancer Sixth Edition Stage Distribution 
(%) for Ovarian Cancer by Histology, United States, 2007 to 2013. 
Source: Torre et al., 2018 
 
  
 While HIPEC is an up-and-coming procedure with regards to advanced ovarian 
cancer, its application has been fairly extensively studied and efficacy well-proven with 
other types of malignancies. HIPEC is now the standard of care when it comes to the 
treatment of peritoneal pseudomyxomas and peritoneal mesotheliomas.6 HIPEC is also 
on its ways to being added to standard of care of many types of colorectal malignancies, 
as it has been proven superior to standard line therapy alone in various clinical studies.6–8 
The status of HIPEC as a promising, effective treatment for these types of cancer is very 
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encouraging for its potential use in treating advanced ovarian cancers. These cancers 
share similarities, specifically when it pertains to the majority of their lifespan within to 
the peritoneal cavity. Similar to colorectal cancers, ovarian cancers spend most of their 
time growing within the peritoneal cavity, which makes ovarian cancer a prime candidate 
for HIPEC. Ovarian cancer does have the ability to metastasize beyond the peritoneal 
cavity, however, disease at this stage would not benefit from HIPEC (or any 
intraperitoneal therapy), and would require systemic treatment. With the advanced 
presentation of ovarian cancer, innovative treatments such as HIPEC are necessary to 
continue to battle this disease. This paper will analyze the status of standard treatment for 
advanced ovarian cancers, explain the technique and rationale for HIPEC, and discuss 
current studies that hold the evidence for introducing HIPEC as a primary treatment for 
advanced ovarian cancer. 
 
 
Standard Treatment 
 Advanced ovarian cancer has been a growing issue for decades. Physicians 
and scientists have constantly been working to battle this disease with the various 
therapeutic agents available to them, creating new treatments when resistance 
occurs and developing maintenance drugs to hold of recurrence for as long as 
possible. This is a very difficult task, considering that just thirty years ago, the 
response rate to frontline therapy was only 40-50%, followed by a median survival 
of only twelve to fifteen months.9 The treatment of advanced ovarian cancer started 
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long ago, however, the standard treatment as it is known today truly took a turn 
roughly twenty-three years ago. Prior to 1996, the standard treatment for advanced 
ovarian cancer was an alkylating agent (generally cyclophosphamide) and a 
platinum based chemotherapy agent (Cisplatin).9 The Gynecologic Oncology Group 
(GOG) released a study9 on January 4th, 1996 in the New England Journal of 
Medicine that changed the direction of frontline treatment for advance ovarian 
cancer. This study aimed to challenge the current alkylating agent plus Cisplatin 
standard of treatment with the addition of Paclitaxel. Paclitaxel was developed in 
1989, and immediately showed promise as a frontline therapy.9 The study 
conducted by the GOG in 1996 had a sample size of 216 patients that met all criteria 
for study entry. The results of the study showed a complete response in 51% of  
 
Figure 3: Overall Survival according to Treatment Group 
Source: McGuire et al., 1996 
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women receiving Cisplatin plus Paclitaxel, whereas the group receiving the current 
standard (Cisplatin plus Cyclophosphamide) only saw a complete response in 31% 
of patients. There was also a significant difference in the progression-free survival 
(PFS) and overall survival (OS) of each treatment group. The PFS was 18 months for 
the Paclitaxel arm compared to only 13 months for the Cyclophosphamide arm, and 
the OS was 38 months and 24 months, respectively (Figure 3). Finally, the response 
rate improved in the paclitaxel group from 60% to 73%. With all of this taken into 
consideration, the GOG declared that Cisplatin plus Paclitaxel was superior to the 
current standard of Cisplatin plus Cyclophosphamide.10 This study set the stage for 
what is now consider the standard treatment for advanced ovarian cancer, which is 
a platinum-taxane combination therapy. 
Even with a new standard set by the GOG in 1996, the search for more 
effective, and less toxic, therapeutic agents is never over. Carboplatin is an analog to 
Cisplatin and had been proven in the past to display less toxic effects to the patient 
than Cisplatin.10 In 2003, the GOG now turned to different platinum-taxane 
combinations to determine if Carboplatin had a place in the frontline treatment of 
advanced ovarian cancer. The GOG released a study10 in 2003 that compared the 
efficacy and toxicity of Cisplatin plus Paclitaxel to Carboplatin plus Paclitaxel in a 
phase 3 trial. The results of this study were less concrete and positive than the 
previous study in 1996. This study resulted in a “non-inferiority” statement 
regarding Carboplatin in relation to Cisplatin. This means that while Carboplatin did 
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not prove definitively superior to Cisplatin, the patients had a relative equal chance 
of recurrence and survival with both drugs. However, Carboplatin did show a 
decrease in some toxicities generally experienced with chemotherapeutic agents. 
Notable, and statistically significant, differences were seen in grade 3 and 4 
leukopenia (low white blood cell count), gastrointestinal, renal, and metabolic  
 
 
Figure 4: Progression-free (A) and Overall (B) Survival in 631 eligible patients 
Source: Katsumata et al., 2009 
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toxicities. Whereas Carboplatin had significant increase in grade 2 to 4 
thrombocytopenia (low platelet count) and grade 1 to 2 pain. With this GOG study 
and two other large European studies,10–12 Carboplatin plus Paclitaxel has become 
the new frontline treatment for advanced ovarian cancer. Dose-dense Paclitaxel has 
also become a new focus of this now standard frontline treatment.  
Dose-dense refers to the frequency at which the Paclitaxel is given. The 
current dosage standard is 175 mg/m2 Paclitaxel and area under the curve (AUC) 
5.0-7.5 mg/mL per minute Carboplatin administered every 3 weeks.13 However, 
studies are now trying to determine if weekly Paclitaxel is appropriate.13,14 One 
study, conducted by Katsumata et al. showed a notable increase in progression-free 
and overall survival when weekly Paclitaxel was administered (plus Carboplatin 
every 3 weeks) versus the conventional treatment of both Carboplatin and 
Paclitaxel every 3 weeks.13 Figure 4 displays the results of this study graphically. 
While the results from Katsumata et al. were promising, there have been studies 
that did not agree with this assessment.15 With recurrence rates remaining high, 
different therapeutics are always being tested and used in the recurrent and 
persistent settings. 
It is very important to consider resistance when dealing with advanced 
ovarian cancer. Resistance is generally described as a recurrence occurring less than 
six months from the last platinum-taxane based chemotherapy. In these situations, 
it is important to have second-line drugs that could be of potential use. Resistance 
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can either be to the platinum or taxane agent.16 In the case of paclitaxel-resistance, 
docetaxel has been investigated as a secondary treatment.17 One study even argued 
for the exploration and consideration of docetaxel plus carboplatin as a frontline 
therapy.17 In the case of a platinum-resistant disease, there are a range of 
monotherapies that have been standardly used, including gemcitabine, pegylated 
liposomal doxorubicin, topotecan, irinotecan, weekly paclitaxel, and 
bevacizumab.16,18,19 At this time, there is little research into the exact impact many 
of these drugs may have on advanced ovarian cancer, and much more research is 
needed to find their place within the treatment regimen. One drug that has been 
recently studied very closely is bevacizumab. Bevacizumab is an anti-angiogenic 
drug, belonging to a class of drugs that recently have been identified as having 
significant anti-tumor properties.19 This drug targets vascular endothelial growth 
factor (VEGF) receptors (VEGFR) in order to disallow angiogenesis, which has 
proven to be a crucial aspect in the proliferation and metastasis of cancer cells.14  
 It is important to note that surgical resection is a quintessential part of the 
treatment of most solid tumors, including advanced ovarian cancer. The goal of 
surgical intervention with regards to solid tumors, has always remained the same – 
macroscopic cytoreduction. Cytoreduction is always a part of the primary treatment, 
whether it be before any treatment (primary) or between chemotherapy treatments 
(interval), it is an absolutely necessary part of the standard frontline treatment.20 
The therapeutic regimens described above are always given to the patient in the 
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adjuvant setting (after surgery), and sometimes in the neoadjuvant setting (prior to 
an interval surgery), depending on the radiographic analysis of disease progression. 
Despite some success in the frontline therapy, there is always need for new, 
innovative procedures. HIPEC has recently become one of those innovations. As this 
paper will discuss, there is strong evidence-based rationale for HIPEC in the setting 
of advanced ovarian cancer, however, the procedure currently lacks technical 
standardization and homogeneity with regards to its indication. 
 
Rationale for HIPEC 
 The argument for adding HIPEC as a standard part of the treatment regimen 
for advanced ovarian cancer is very logical. Each aspect of HIPEC has been proven to 
increase cytotoxicity and improve outcomes in patients suffering from cancer. If we 
break down the procedure, it becomes more clear. HIPEC is the administration of 
intraperitoneal chemotherapy that has been heated to a safe, but effective, 
temperature intraoperatively after significant cytoreductive surgery (primary, 
interval or secondary). There are sound arguments for each part of HIPEC in the 
literature that make it an effective treatment for advanced ovarian cancer. 
Intraperitoneal versus Intravenous 
Intraperitoneal (IP) chemotherapy has been a heavily studied treatment 
modality for various different kinds of cancers that generally remain within the 
peritoneal cavity. So it would come as no surprise to learn that it has also been 
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heavily studied with regards to advanced ovarian cancer. IP chemotherapy has been 
studied as a form of treatment for peritoneal metastases as early as 1955.21 
However, the number of experimental studies has significantly increased within the 
past two decades, around the same time that treatment was being switched from 
cisplatin plus cyclophosphamide to cisplatin plus paclitaxel. One study was released 
in 1996, just about 11 months after the GOG released the superiority trial moving to 
paclitaxel, which demonstrated very early on that IP cisplatin showed significant 
improvement in overall patient outcomes.22 This study, conducted by Alberts et al 
and released in the New England Journal of Medicine (NEJM), was attempting to 
directly compare the efficacy of intravenous (IV) cisplatin plus IV cyclophosphamide 
to IP cisplatin plus IV cyclophosphamide, keeping in mind that the switch to 
paclitaxel had not fully taken effect given the proximity to the release of the GOG 
superiority study. This was a controlled randomized study, including patients with 
stage III disease that were able to complete a cytoreductive surgery leaving no 
tumor nodule greater than 2 cm. Randomization occurred to either the IV only arm, 
or the IP plus IV arm. Both groups received cyclophosphamide at 600 mg/m2 over 
60-90 minutes. The IV only arm received cisplatin 100 mg/m2 administered at a rate 
of 1 mg per minute. The IP arm received cisplatin at 100 mg/m2 mixed with 2 liters 
of saline and warmed to body temperature, administered through an IP catheter. 
These cycles were repeated every 3 weeks for a total (goal) of six cycles per patient. 
There were 546 eligible patients enrolled onto the study, giving a substantial and 
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adequate sample size. The median survival for patients was 41 months in the IV only 
arm and 49 months in the IP plus IV arm (Figure 5). Survival is not the only findings 
of significance in a study such as this one – toxicity to the patient must also be 
considered. Overall, toxicities we very similar between the two groups, with the IP 
group only having a significant increase in abdominal pain, which (according to the 
investigators) is expected. This study clearly shows the promise of IP chemotherapy  
 
Figure 5: Survival of 546 Eligible Patients with Stage III Ovarian Cancer Who 
Were Randomly Assigned to Treatment with IV or IP Cisplatin 
Source: Alberts et al., 1996 
 
as a treatment for ovarian cancer, even without the added effects of hyperthermia 
and the timing of HIPEC. IP chemotherapy was continued to be studied beyond 
1996, with two notable trials: one conducted by Markman et al in 2001 and the 
other by Armstrong et al in 2006.23,24 The first study, Markman et al, also had a 
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significant sample size of 462 eligible patients. This trial contained two treatment 
arms, the first receiving paclitaxel (135 mg/m2 over 24 hours) IV followed by 
cisplatin (75 mg/m2) IV on day 2 for a total of six cycles. The second treatment arm 
received carboplatin (AUC 9) IV for two course every 28 days, followed 4 weeks 
later by paclitaxel (135 mg/m2 over 24 hours) IV plus cisplatin (100 mg/m2) IP on 
day 2, every 3 weeks for a total of six cycles. PFS was found to be longer in the 
experimental arm receiving IP cisplatin rather than IV, 27.9 months compared to 2.2  
 
Figure 6: Progression-Free (A) and Overall (B) Survival 
Source: Armstrong et al., 2006 
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months. This study also showed a significant improvement in OS, with a median 
survival of 63.2 months in the IP arm and 52.2 months in the IV only arm. The 
second study mentioned above, Armstrong et al in 2006, further confirmed the 
findings of these two previous studies. This study was a perfect intermediate 
between the two previous studies to definitively confirm cisplatin IP as a beneficial 
treatment modality. Armstrong et al. conducted their study with the newly accepted 
standard treatment of cisplatin plus paclitaxel, and they did not include the two 
courses of carboplatin seen in Markman et al. The standard treatment arm received 
paclitaxel (135 mg/m2 over 24 hours) IV on day 1 followed by cisplatin (75 mg/m2) 
IV on day 2, every 3 weeks for a total of six cycles. The experimental arm, or IP arm, 
received paclitaxel (135 mg/m2 over 24 hours) IV on day 1 followed by cisplatin 
(100 mg/m2) IP on day 2, as well as paclitaxel (60 mg/m2) IP on day 8. This 
treatment arm also occurred every 3 weeks for a total of six cycles. Once again, the 
sample size was sufficient to make substantial conclusions, with 415 eligible 
patients. As we saw in the other studies, PFS and OS were significantly increased in 
the experimental (IP) arm (Figure 6). These three studies22–24, spanning a decade, 
clearly show that the intraperitoneal delivery of chemotherapy is beneficial for 
patients with advanced ovarian cancer. This confirms the effectiveness of one aspect 
of HIPEC. 
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Hyperthermia 
Hyperthermia has been studied as an effective tool on its own to directly 
affect neoplastic cells21,25–28, but also to enhance the cytotoxicity of chemotherapy 
agents used to treat cancer.21,28,29 According to Dickson et al.25, hyperthermia’s effect 
on cancer cells dates back all the way to 1866. These effects have since been studied 
at length and the results of such studies adds tremendous value to the rationale for 
adding HIPEC to treatment regimens. In 1967, Cavaliere et al.26 showed that 
hyperthermia, specifically at 42 degrees Celsius, had an irreversible and negative 
impact on neoplastic cellular respiration. The greatest outcome of these 
observations was that normal cells were left relatively unharmed by the 
hyperthermic environment. Studies conducted later by Dickson et al. in 1972 
confirmed the same findings. More specifically, this group found that oxygen uptake 
was actually increased at 39 and 40 degrees Celsius, however, the irreversible 
damage came about roughly at 42 degrees Celsius. This confirmed the findings of 
Cavaliere et al., however, it added the notion that a specific hyperthermic range 
must be kept so as not to increase respiration in these cells. They determined 42.0 
degrees Celsius to be the lowest temperature at which an irreversible inhibitory 
effect on respiration and proliferation will occur (this study was carried out using 
breast tumor cells).25 As discussed above, anti-angiogenesis has become an 
incredibly popular therapy for cancer, even if most beneficial in a maintenance 
phase. It has been shown that hyperthermia can also decrease, or even completely 
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stop the blood flow, in the microcirculation of certain malignant tumors.28 As 
mentioned, this direct affect that hyperthermia has on neoplastic cells has been 
studied for over a century, however, with new drugs and new standard treatments, 
hyperthermia is now known to be beneficial in completely new ways. There is 
substantial literature on the indirect effect that hyperthermia has on neoplastic 
cells, namely the thermal enhancement of chemotherapeutic drugs.21,28 This 
increase in cytotoxicity of therapeutic drugs when exposed to high temperatures is 
most likely due to an increased membrane permeability within malignant cells, 
leading to improved membrane transport of the given drug.21 Additional factors 
discussed in Recent Results in Cancer Research (Vol. 169)21 include alteration of 
drug pharmacokinetics and excretion, increase in drug penetration, temperature-
dependent increases in drug action, and inhibition of cellular repair mechanisms. 
This enhancement of chemotherapeutic drugs cytotoxicity has been seen to occur 
around 39 or 40 degrees Celsius, before the direct effects of hyperthermia take 
effect.21 These varying temperatures must be taken into consideration when 
deciding the temperature at which HIPEC should be administered. Hyperthermia 
does not enhance the ability of all chemotherapeutics equally, some respond to the 
increased temperature better than others. Takemoto et al.29 found that alkylating 
agents such as melphalan, cyclophosphamide and ifosfamide are observed to have 
the highest thermal enhancement ratios. Also of note, this same study proclaimed 
that cisplatin may be a favorable second option to the alkylating agents mentioned 
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above.29 This greatly enhances the rationale for HIPEC to be used in advanced 
ovarian cancer, as cisplatin is considered one of the standard chemotherapeutic 
agents to be used for the disease. The various effects of hyperthermia, both direct 
and indirect, on neoplastic cells is of crucial significance to further the rationale for 
HIPEC when treating advanced ovarian cancer. 
 
Surgical Timing 
When you combine the scientific evidence supporting intraperitoneal 
delivery of chemotherapy and the cytotoxic effects of hyperthermia, the use of 
HIPEC seems clear. However, there is even more compelling evidence for this 
approach with regards to peritoneal metastases. HIPEC is administered 
intraoperatively, immediately following a cytoreductive surgery. The key advantage 
here is that any adhesions that may be present within the peritoneal cavity would 
have been lysed at the time of complete cytoreduction. Regular IP chemotherapy is 
given weeks after a cytoreductive surgery, allowing adhesions to form within the 
peritoneal cavity, which can hinder the ability of the chemotherapeutic agent to fully 
circulate throughout the abdomen. By administering HIPEC immediately after the 
cytoreductive surgery, before any new adhesions have time to form, there is a 
higher probability that the drug being used will reach the entire peritoneal cavity.30 
This is necessary because the role of these IP treatments is to attack residual disease 
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that is not resectable via surgical intervention. The timing of HIPEC administration 
should absolutely be added to the list of qualifying benefits of the procedure. 
  
Safety and Feasibility 
Finally, with all these beneficial aspects of HIPEC, it is important to consider 
the safety of the patient. The safety and feasibility of HIPEC has been studied in 
depth. Many studies have shown that HIPEC is absolutely safe for the treatment of 
human peritoneal disease, and that it does not notably or significantly increase the 
morbidity and mortality rates within the patient population.30–34 With the rationale 
for HIPEC being so immensely supported by scientific evidence, the stage has been 
set for further analysis of the procedure via controlled randomized studies. In the 
past decade, there have been an increasing number of studies with the goal of 
considering HIPEC as a complimentary element of the standard of care in advanced 
ovarian cancer. 
 
Technique 
 HIPEC is a very technical approach and it does require a fair amount of 
expertise and specificity when carrying out this procedure. Unfortunately, there is 
no standardization when it comes to the technique of carrying out a HIPEC 
procedure.35 There is variability in every study when it comes to every aspect of the 
procedure, including open (coliseum) vs closed technique, flow rate, temperature, 
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length of perfusion, and even the drug that is used. Ferron et al.35 conducted a 
survey of thirty-four French institutions that are regularly using HIPEC for a variety 
of cancers. This survey confirmed the lack of standardization and the need for 
homogeneity when it comes to HIPEC technique. Some aspects of the administration 
seem to be agreed upon, such as the need for a small, expert team to carry out the 
procedure.32,35  The variability in technique is very apparent in the subsequent 
overview of different clinical trials in the past two decades. 
 
RECENT STUDIES 
 There has been an increase in the number of HIPEC trials over the past 
twenty years. The technique has been studied with increasing frequency in 
peritoneal pseudomyxomas, peritoneal mesotheliomas, and colorectal cancer.6,8 The 
advancement seen in these diseases, and the promise HIPEC has shown in helping 
successfully treat them, has clearly influenced the interest now in HIPEC’s role in 
advanced ovarian cancer. Investigators have been looking for any place within the 
treatment regimen to add HIPEC as a complimentary treatment modality. Many 
studies focus on the recurrent and persistent setting, however, some do explore the 
role HIPEC may have as a frontline treatment for the disease. Recently, quality of life 
(QOL) has become an increasingly important study parameter, therefore it is 
absolutely crucial to consider QOL when discussing the advancements with HIPEC. 
Below, recent studies are discussed in detail, followed by a discussion on what is 
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necessary in order to fully accept HIPEC into the treatment regimen of advanced 
ovarian cancer. 
 
Primary Disease 
 Many studies have been conducted within the last decade regarding HIPEC 
and its role specifically with primary advanced ovarian cancer. To date, this data 
mainly includes phase I and phase II trials. Phase I trials aim to determine the safety 
and appropriate dosing of the chemotherapeutic agent, whereas the phase II trials 
are challenging the standard treatment to some extent and make an argument for 
the addition of HIPEC. These studies offer insight in the future role HIPEC may play 
in the treatment of primary disease. 
 It is important to first discuss the phase I primary studies that have been 
conducted to establish the appropriate dosage that should be seen in the later phase 
II studies. In 2007, Lentz et al.34 conducted a phase I study with the goal of 
determining the maximal tolerated dose (MTD) of carboplatin when used as the 
chemotherapeutic agent in a HIPEC system. This study used an escalating dose of 
carboplatin (400, 600, 800 and 1000 mg/m2). Patients enrolled on this study were 
required to have an optimal cytoreduction, which was defined as residual 
intraperitoneal disease of less than 1 cm. The investigators chose to use the closed 
abdomen technique, as opposed to the coliseum technique. A flow rate was held 
between 600 and 800 ml/min, and the drug was perfused for 90 minutes. The 
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results of this study concluded that when using carboplatin, the MTD is 1000 
mg/m2, as they saw no significant increase in toxicities relative to the lower 
dosages. They had moved to 1200 mg/m2, however this resulted in an unacceptable 
rate of grade 4 toxicities. As discussed in the standard treatment section, drugs 
other than carboplatin are considered in frontline therapy, specifically cisplatin. 
There is also evidence that supports cisplatin in IP treatment over the use of 
carboplatin.36,37 This has been considered in another phase I study conducted in 
2014 by Zivanovic et al.,31 which is further discussed in the recurrent or persistent 
disease section. Phase I studies determining MTD and confirming the feasibility of a 
treatment pave the way for further investigation into the efficacy of that treatment.  
Lim et al.38 released a report in 2009 regarding an interim analysis of a phase 
II trial incorporating HIPEC in the treatment of primary advanced EOC. HIPEC was 
administered as cisplatin (75 mg/m2) at 41.5 degrees Celsius over 90 minutes using 
a closed technique (as opposed to the coliseum). No set flow rate was given during 
this trial. This study specifically reports that the patients’ abdomen was repeatedly 
shaken during the HIPEC perfusion in order to ensure proper distribution of the 
chemotherapeutic agent. A total of 30 eligible patients were treated with HIPEC 
following extensive cytoreductive surgery; patients were only administered HIPEC if 
the residual disease was less than 1 cm. All patients had either stage III (n = 25) or 
IV (n = 5) disease. It is important to note that 14 patients (47%) received 
neoadjuvant therapy, while the 16 (53%) other patients received HIPEC on their 
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primary surgery. All patients received adjuvant carboplatin plus paclitaxel (cycle 
dependent on neoadjuvant status). While this is an interim analysis, the response 
rate seen within this study is definitely encouraging. Twenty-eight patients (93%) 
saw a complete response, with only 2 patients (7%) experiencing progressive 
disease. As with most interim analysis, this study was unable to make a definitive 
statement regarding survival, and called for further phase II investigation.  
 A multicenter, phase II, Italian study released in 2011 offered the exact kind 
of further investigation called for by the previous study. This study, conducted by 
Deraco et al.,39 focused on the overall survival observed when HIPEC was added to 
the upfront treatment of advanced EOC with peritoneal involvement. Cisplatin and 
doxorubicin were administered during this study; cisplatin was administered at 40 
mg per liter of perfusate and doxorubicin at 15 mg per liter of perfusate.  
 
Figure 7: Overall survival of patients affected by advanced epithelial ovarian 
cancer treated by cytoreductive surgery and hyperthermic intraperitoneal 
chemotherapy. 
Source: Deraco et al., 2011 
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Temperature was kept at 42.5 degrees Celsius, and a flow rate of 700 ml/min was 
maintained. The completeness of the cytoreduction (CC) was scored as follows: CC0: 
no residual disease; CC1: residual nodules measuring less than 2.5 mm; CC2: 
residual nodules measuring between 2.5 mm and 2.5 cm; and CC3: residual nodules 
greater than 2.5 cm.39,40 Twenty-six eligible patients were enrolled onto this study, 
all of which had either stage III or IV disease and had not received any previous 
treatment. The median PFS was 30 months, with a 5-year OS and PFS of 60.7% and 
15.2%, respectively (Figure 7). According to the investigators, this is at the very 
least comparable to the standard of care, and the results are favorable for HIPEC as 
a complimentary frontline therapy. While there is some evidence to point to HIPECs 
use in frontline therapy, many more studies have been conducted in the recurrent 
setting due to HIPEC’s use as a salvage therapy.41 Salvage therapy is explored when 
all standard of treatment have failed and new, more experimental measures are 
taken to help the patient. 
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Giorgio et al.41 released a phase II trial in 2008 that established scientific 
evidence to support the use of HIPEC in the treatment of advanced ovarian cancer, 
not only for primary disease but also recurrent or persistent disease. This Italian 
study enrolled patients with either primary or recurrent stage III or IV ovarian 
carcinoma. The CC score was assessed as described above. One of the only 
statistically significant outcomes was in reference to the CC score. It was seen, and  
 
Figure 8: Five-year Survival and Completeness of Cytoreduction (CC) score  
Source: Giorgio et al., 2008 
 
 
this is a recurring theme throughout these types of trials, that the completeness of 
cytoreduction is very indicative of survival (Figure 8). Cisplatin was the drug of 
choice in this study, with a maintained flow rate of 500 ml/min, and temperature 
maintained between 41-43 degrees Celsius. The heated chemotherapy was only 
perfused for 60 minutes in this trial and the cisplatin dosage was calculated at 75 
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mg/m2.  A total of 47 eligible patients were added to this study, 22 with primary 
disease and 25 with recurrent disease. This study showed promising results for both 
primary and secondary approaches using HIPEC. While this study looked at both 
primary and secondary, in the discussion the investigators mention the abundance 
of literature regarding HIPEC as a treatment for recurrent disease (secondary 
approach). The authors explain that this is most likely due to the historical use of 
HIPEC as a salvage therapy. It is therefore, important to consider past studies that 
have looked more specifically at recurrent and persistent disease, as discussed in 
the next section. 
 Having said that, there has been enough satisfactory evidence within the 
phase II trials to begin phase III trials at the primary stage of diagnosis. Very recent 
evidence displayed in a phase III trial confirms much of the speculation in the phase 
II trials that HIPEC is a quality treatment modality for newly diagnosed, primary, 
previously-untreated advanced ovarian cancer. Van Driel et al.42 released a  
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Figure 9: Kaplan-Meier Estimates of Recurrence-free (A) and Overall (B) 
Survival 
Source: van Driel et al., 2018 
 
report of a phase III trial in 2018. Phase III trials aim to directly compare a new 
treatment that has been proven as safe, feasible approach to the standard of 
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treatment.43 Ideally, this requires a controlled randomized study. This is exactly the 
type of study that was conducted by van Dreil et al. in 2018. This was a large 
multicenter study that accrued 245 eligible patients with stage III disease, a sample 
size that should result in significant outcomes. This study was designed with two 
treatment groups: one receiving the standard treatment, and the other receiving 
standard treatment plus HIPEC during an interval surgery. All patients in this cohort 
received three cycles of neoadjuvant carboplatin (AUC 5 or 6 mg/mL per minute) 
plus paclitaxel (175 mg/m2). At completion of these three cycles, patients with 
stable disease underwent cytoreductive surgery. Randomization occurred in the 
operating room for patients with complete or optimal cytoreduction. Complete 
cytoreduction was defined as no evidence of residual disease, while optimal 
cytoreduction was defined as one or more residual tumors measuring no more than 
2.5 mm. The open, or coliseum, technique was used, with cisplatin (100 mg/m2) plus 
perfusate heated to 40 degrees Celsius and a flow rate of 1000 mL/min maintained. 
The chemotherapeutic agent was perfused over a time period of 90 minutes. This 
study resulted in an increased recurrence-free and overall survival in the HIPEC 
group, relative to the no HIPEC group (Figure 9). In the end, van Driel et al. 
concluded that complete or optimal cytoreductive surgery plus HIPEC resulted in 
longer survival than cytoreductive surgery alone. This is one of the most recent and 
extensive trials regarding the use of HIPEC in newly diagnosed advanced ovarian 
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cancer, and it resulted in some very compelling data that strengthens the argument 
for adding HIPEC into the standard of care. 
 
Recurrent or Persistent Disease 
There is a significant amount of data aimed at determining the efficacy of 
HIPEC in the recurrent setting of advanced ovarian cancer. Again, this is mainly a 
byproduct of HIPEC starting out primarily as a salvage therapy for patients with 
persistent disease.41 The use of HIPEC in the recurrent setting dates back to at least 
the early 1990s44,45 and continues through the turn of the century, with phase III 
trials starting in the early 2000s.30 The early studies conducted were at the forefront 
of adding HIPEC as a treatment for advanced ovarian cancer, specifically in the 
context of heavily pre-treated disease. 
Discussed in a report released in 2003, Chatzigeorgiou et al.44 conducted a 
phase II trial of HIPEC in the recurrent setting, gathering patients over a five-year 
period from 1993 to 1998. This study utilized cisplatin as its primary 
chemotherapeutic drug during the HIPEC procedure, however, the dosage used was 
only 50-70 mg/m2. Over the five-year period, twenty patients were enrolled onto 
this study. All patients had recurrent disease that had previously been heavily 
treated with surgery and systemic chemotherapy, which points to HIPECs early 
emergence as a salvage therapy. This early study used the closed technique, and 
administered the cisplatin (50-70 mg/m2) at 39-40 degrees Celsius over a period of 
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2 hours. This study, like those described above, found that the extent to which the 
disease was debulked prior to HIPEC was a key survival factor. This study ultimately 
concluded that this procedure showed promise in treating recurrent ovarian cancer, 
but of course more evidence was needed to fully adopt the technique. These phase II 
results were confirmed in 2004 by Zanon et al.45 This study enrolled patients 
between 1998 and 2003, almost immediately following the preceding trial. The 
investigators were able to enroll 30 eligible patients. This study had more specificity 
in the HIPEC technique used: temperature held between 44 and 46 degrees Celsius, 
flow rate between 900-1200 ml/min, cisplatin 100 or 150 mg/m2, and a 60-minute 
perfusion time. This study also rated the surgical based on CC score40 as described 
previously. Once again, patients with a more in depth debulking procedure were 
shown to have an increased survival benefit. The investigatory team concluded that 
HIPEC as a technique should not replace the standard treatment, but its addition to 
IV treatment is warranting of further exploration. 
Despite early phase II studies, the first phase I study to determine the 
appropriate cisplatin dosage specifically in the case of ovarian cancer and HIPEC 
was not piloted until 2014. Zivanovic et al.31 conducted a study in Germany in 2014 
designed as a phase I study aimed at determining the appropriate dosage of 
cisplatin when used during a HIPEC procedure in the treatment of advanced ovarian 
cancer. This study focused on patients with platinum-sensitive recurrence of EOC, 
which means patients recurred greater than six months from their previous 
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platinum-based treatment. Similar to the phase I study discussed above, the 
methodology included a standard 3+3 dose-escalation, which requires three 
patients to receive the lowest dose with acceptable toxicities to move on to the next, 
and so on. The three doses chosen were 60, 80 and 100 mg/m2, which makes sense 
considering the previous findings regarding intraperitoneal cisplatin requiring 10 
times less drug to have the same tissue penetration than carboplatin.36 This trial had 
a specific temperature range of 41-43 degrees Celsius, however, a specific flow rate 
was not noted in the methods. A 90-minute timeframe was established for the 
delivery of the cisplatin. It was concluded that the maximal level of cisplatin 
delivered as HIPEC should be set at 100 mg/m2. Overall, this team indicates the 
need for increased study into the role of HIPEC in the recurrent setting to determine 
the efficacy of the treatment when compared to the standard of care. 
Further phase II data was released by Ceelen et al.46 in 2009. This Belgium 
study enrolled patients over a seven-year period, totaling forty-two eligible patients 
during that time. These patients all had recurrent disease that, once again, had been 
heavily pre-treated with surgery and systemic chemotherapy. This study took 
platinum sensitivity into account, offering cisplatin (100-250 mg/m2) and 
oxaliplatin (460 mg/m2 in dextrose 5%) based on presumed platinum-sensitivity or 
hypersensitivity. Patients receiving cisplatin intraoperatively were perfused for 90 
minutes, whereas those receiving oxaliplatin were perfused for only 30 minutes. 
According to Ceelen et al., the shorter duration of chemoperfusion with oxaliplatin is 
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based on a more rapid systemic absorption and a more pronounced locoregional 
toxicity with longer chemoperfusion times.46,47 The investigators preferred the open 
(coliseum) technique and held the temperature between 40.5 and 41 degrees 
Celsius. The median OS for this group was 37 months, with a PFS of 13 months. As 
seen previously, the factor leading to a significant increase in survival was 
completeness of cytoreduction (CC score). Also noted in this study was a significant 
difference in survival among differentiated tumors and undifferentiated tumors, 
with an increase in survival seen in the former. Overall, this study confirmed much 
of what has been previously reported: HIPEC is a safe and feasible approach to 
recurrent ovarian cancer. The authors called for a phase III trial comparing the 
standard of care to the new HIPEC treatment. 
Just as Ceelen et al. was calling for a randomized phase III trial, Spiliotis et 
al.30 was concluding a trial that aimed to do just that. This Greek study was 
published in the Annals of Surgical Oncology in 2015, with data gathering over an 
eight-year between 2006 and 2013. During this time, one hundred and twenty 
patients with either stage III or IV ovarian cancer were enrolled onto the study. This 
study also considered platinum sensitivity in their analysis, which brings about a 
very key point of discussion with regards to HIPEC’s efficacy. Patients were 
randomized into two treatment groups preoperatively: a HIPEC group and a non-
HIPEC group. The non-HIPEC group (n=60) received standard treatment: 
cytoreductive surgery followed by systemic chemotherapy. The HIPEC group (n=60) 
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was further broken down based on platinum sensitivity. Platinum-sensitive patients 
(n=34) underwent cytoreductive surgery followed by intraoperative HIPEC 
(cisplatin 100 mg/m2 plus paclitaxel 175 mg/m2 at 42.5 degrees Celsius over 60 
minutes), with routine adjuvant systemic chemotherapy. Platinum-resistant 
patients (n=26) underwent cytoreductive surgery, however, they differed in the 
drug used during HIPEC (doxorubicin 35 mg/m2 plus [paclitaxel 175 mg/m2 or  
 
Figure 10: Kaplan-Meier survival plot, HIPEC versus no HIPEC, p = 0.006 
Source: Spiliotis et al., 2015 
 
mitomycin 15 mg/m2] at 42.5 degrees Celsius over 60 minutes), with routine 
adjuvant systemic chemotherapy. Interestingly, the open (coliseum) approach was 
used in 2/3 of the HIPEC group, while the other 1/3 were completed using the 
closed approach. The results of this study were resounding, and the clearest 
demonstration to date of HIPECs efficacy in the recurrent ovarian cancer. The mean 
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OS in the HIPEC group was 26.7 months, which was statistically different from the 
non-HIPEC group mean OS of only 13.4 months (Figure 10). These results held true 
even when broken down by stage III and IV disease, with improved survival in the 
HIPEC group for both disease stages. The platinum-sensitive HIPEC group yielded 
significantly longer survival (26.8 months) versus the platinum-sensitive non-HIPEC 
group (15.2 months). However, while notable, the was no statistical difference in the 
platinum resistance HIPEC versus non-HIPEC groups with survival of 26.6 months 
and 10.2 months, respectively. Also important to note, was the fact that there was no 
difference between the platinum-sensitive and platinum-resistance groups that 
received HIPEC (26.8 months and 26.6 months, respectively). A common theme has 
developed based on the CC score and survival, and this study was no different; a CC 
score of 0 yielded statistically longer survival periods than a CC score of 2. It would 
come as no surprise, based on the results of this study, that the investigators 
concluded that cytoreductive surgery accompanied with HIPEC offers significant 
survival benefits for patients with recurrent EOC, independent of platinum 
sensitivity. While these results are incredibly encouraging, there are examples of 
studies that have resulted in conflicting conclusions.  
A similar study was conducted in Brazil, around the exact same time as the 
previous Greek study. Baiocchi et al.48 released a report in the Annals of Surgical 
Oncology just one year after Spiliotis et al. This 2016 report had quite conflicting 
results. Seventy-nine patients were identified from May 2000 to January 2014, and 
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broken down into two groups: SCR (secondary cytoreductive surgery) and SCR plus 
HIPEC, with fifty and twenty-nine patients, respectively. Although the breakdown of 
the study was very similar to Spiliotis et al., it suffers from several limitations, not 
least of which is its retrospective nature. Without the control and randomization of  
 
Figure 11: Disease-free (A) and overall (B) survival for patients with SCR and 
SCR+HIPEC 
Source: Baiochhi et al., 2016 
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a prospective trial, this study lacked homogeneity within the HIPEC group. The 
drugs chosen being a prime example; the regimens used in these cases included 
mitomycin C (10 mg/m2) plus cisplatin (50 mg/2), cisplatin (50 mg/m2) plus 
doxorubicin, cisplatin (50 mg/m2) alone, and oaxaliplatin. Nevertheless, this study 
did find that there was no statistical difference in disease-free survival between the 
SCR and SCR plus HIPEC groups (18.6 months and 15.8 months, respectively). The 
same non-superiority finding was found in OS, with the SCR group resulting in 59.3 
months and the SCR plus HIPEC group resulting in 58.3 months (Figure 11). The 
investigators concluded that there is no benefit to adding HIPEC versus SCR alone, 
however, they did indicate the limitations to their study. More than anything, this 
study showed the importance of homogeneity throughout the practices and trials of 
HIPEC, something that clearly has been lacking in the studies discussed thus far. 
 
Quality of Life  
 Quality of life (QOL) has become increasingly important in medicine as 
physicians develop a treatment plan for their patients, and QOL is now thought of as 
one of the key factors that determine the value of a therapy provided to patients 
with advanced cancer.49 QOL questionnaires and assessments are therefore 
becoming increasingly common within therapeutic trials. Many studies will add a 
QOL survey to their study to get track how patients deal with the new treatment 
being tested. Driel et al.,42 which was discussed in detail above, was a phase III trial 
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comparing a cytoreductive surgery group versus a cytoreductive surgery plus HIPEC 
group that incorporated QOL assessment into their study design. This study utilized 
the European Organization for Research and Treatment of Cancer (EORTC) Quality 
of Life Questionnaire-Core 30 (QLQ-C30), Quality of Life Questionnaire-Ovarian 
Cancer Module (QLQ-OV28), and Quality of Life Questionnaire-Colorectal Cancer 
Module (QLQ-CR38) to fully capture the health-related changes in QOL of the 245 
patients participating on this trial. These questionnaires were given to patients 2 
weeks prior to randomization (baseline assessment), before the fourth cycle of 
chemotherapy, 1 week after completion of chemotherapy and during all subsequent 
follow up appointments at 3, 6, 9, 12, 15, 18, 21, and 24 months. This study found 
that the incidence of adverse events was similar within the two groups, with no 
statistical difference between the groups. Adverse events of grade 3 or 4 were 
reported in 30 patients (25%) in the surgery only group and 32 patients (27%) in 
the surgery plus HIPEC group. Overall, the results of the multiple questionnaires 
completed throughout the entirety of study treatment showed no difference in the 
health-related QOL in the HIPEC group relative to those on the standard treatment 
regimen. While this QOL assessment was incorporated into an ongoing prospective 
trial, other investigators will create separate studies to solely focus on health-
related QOL of patients undergoing specific treatments. 
 Two such studies were released in the Annals of Surgical Oncology in 
2013.49,50 Tan et al. conducted a single center study at the National Cancer Centre of 
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Singapore. This study aimed to compare the QOL of patients undergoing surgery 
plus HIPEC to the QOL of disease-free cancer patients. Twenty-seven HIPEC patients 
were enrolled onto the study and compared to 393 participating disease-free 
patients that were currently not receiving any kind of treatment. The investigators 
used the EORTC QLQ-C30 questionnaires. This study was not limited to ovarian 
cancer, however, the QOL results and conclusions made regarding HIPEC would be 
comparable to patients with ovarian cancer undergoing the same treatment. 
Twenty-two patients were female (81%), 15 (55%) of which had ovarian cancer; 5 
(19%) patients had appendiceal carcinoma, and the remaining 4 (15%) patients had 
colorectal carcinoma. According to this study, patients that usually undergo 
cytoreductive surgery alone see a return to baseline in QOL about 4-6 months after 
the procedure. In the end, these investigators were able to conclude that there was 
no significant difference in the QOL of patients receiving HIPEC relative to the 
reference group (disease-free cancer patients), and stated that QOL impairment 
should not deter surgeons from offering cytoreductive surgery plus HIPEC in the 
management of peritoneal carcinomatosis.50  
 Tsilimparis et al.49 conducted a very similar QOL study in a combined effort 
between Charite Universitatsmedizin Berlin and Emory University School of 
Medicine. Similar to the previous study, this patient population was not limited to 
ovarian cancer, but instead included any patients undergoing surgery plus HIPEC 
for peritoneal carcinomatosis. This study accrued ninety patients with a range of 
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disease including colorectal cancer (21%), ovarian cancer (19%), peritoneal 
psuedomyxoma (16%), appendiceal cancer (16%), gastric cancer (10%), and 
peritoneal mesothelioma (13%). The EORTC QLQ-C30 wasutilized during this study, 
and was completed by patients in the pre-surgery setting (baseline), 1 month, 6 
months and 12 months post-operatively and then yearly after that point. This 
investigatory group was able to determine that patients undergoing surgery plus 
HIPEC for the various cancers listed above were able to return to their baseline 
status within the first postoperative year. The investigators concluded that health-
related QOL should never be the reason to deny HIPEC as treatment to patients that 
may benefit from its application. 
 
 
 
CONCLUSION 
 
HIPEC is an innovative procedure that has been proven as an effective treatment 
in various peritoneal cancers, including peritoneal pseudomyxomas, mesotheliomas and 
colorectal metastases. It combines the therapeutic benefits of intraperitoneal 
chemotherapy delivery with the cytotoxic benefits of hyperthermia. Both aspects of this 
procedure have been heavily studied, and alone they have both been very successful. 
Intraperitoneal chemotherapy has increased the survival rates of patients in various 
studies.22–24 These studies also delivered the chemotherapy a fair amount of time after a 
cytoreductive surgery, which would have allowed adhesions to form . HIPEC offers a 
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solution to any problems that would arise with adhesions interfering with full circulation 
of an IP chemotherapy. Hyperthermia’s effects on neoplastic cells has been studied for 
over a century, and there is a clear consensus regarding the benefits. More recently, 
hyperthermia has been studied for its ability to enhance the cytotoxic effects of many 
chemotherapeutic agents. In theory, by combining these elements, that have proven to 
improve the quality of treatment in advanced ovarian cancer, there should be an increased 
effectiveness of overall treatment and a coupled increase in survival in these patients. 
This is exactly what was seen in the most recent phase III trials involving HIPEC.30,42 
Both of these trials showed that HIPEC significantly improved the outcomes of patients 
relative to standard cytoreductive surgery followed by systemic chemotherapy, both in 
the primary (Driel et al.) and recurrent (Spiliotis et al) settings. While these studies, along 
with the multitude of phase II studies that should he same type of efficacy are promising, 
there are still many issues with the way in which HIPEC is being delivered and studied. 
The manner in which the QOL of a cancer patient is left after they receive 
treatment is of the utmost importance when considering a treatment regimen. This crucial 
element of patient care cannot be forgotten in the pursuit of seek new, innovative 
approaches in the treatment of cancer. It has been seen in the three studies discussed 
above42,49,50 that the health-related QOL of patients undergoing surgery plus HIPEC is not 
affected, relative to reference groups. Patients that receive this therapy are able to return 
to their baseline within the first post-operative year, and overall, their QOL does not 
differ from disease-free cancer patients. With the QOL of these patients protected, 
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HIPEC should absolutely continue as a potential treatment modality for advance ovarian 
cancer. 
The greatest concern seen throughout a review of various studies investigating 
HIPEC is the lack of standardization. The heterogeneity seen within these studies ranges 
from the HIPEC technique utilized (flow rate, temperature, perfusion time, and 
chemotherapeutic agent used) to the time point of utilization (primary versus recurrent). 
With all of these factors lacking standardization, it is difficult to decipher what approach 
is actually most beneficial. The first element to address would need to be the 
chemotherapeutic agent of choice. There seems to be sufficient evidence to point to 
cisplatin as the optimal drug to be administered during HIPEC. This is based off the 
findings that cisplatin cytotoxicity is significantly enhanced with hyperthermia,29 and the 
fact cisplatin has been proven to be more beneficial as an intraperitoneal drug than 
carboplatin (the other standard of treatment drug).36,37 It is also very important to 
standardize the temperature at which HIPEC is administered, due to the fairly small 
cytotoxic window described by Dickson et al.25 Based on this report, the temperature 
should be held as close to 42 degrees Celsius throughout the entire procedure. This is the 
optimal temperature at which the hyperthermia alone would add a cytotoxic effect and 
would allow for the increased in cytotoxicity of cisplatin.21,29 The temperature of HIPEC 
is absolutely crucial, as dipping below 40 degrees Celsius could actually increase the 
respiration seen within malignant cells (39 to 40 degrees Celsius).25 As for the specific 
surgical technique used (closed versus open/coliseum), there is not much evidence 
pointing to one or the other. There seems to be some that believe the open (coliseum) 
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approach allows for increased circulation throughout the peritoneal cavity, however, this 
could be counteracted in the closed technique simply by continuously shaking the belly 
during the administration of HIPEC. This would need to be more directly studied to 
actually point to a difference in these techniques, however, it would be unlikely to result 
in any significant difference. Standardizing these few key aspects of the HIPEC 
procedure would allow for more concrete statements to be made regarding the efficacy of 
HIPEC. With these standardizations in place, more phase III trials should be conducted in 
order to move HIPEC into the standard treatment regimen of advanced ovarian cancer. 
At this point, more phase III trials are needed to definitively confirm HIPEC’s 
efficacy. Having said that, adding more standardization to the sound scientific rationale, 
the countless studies proving efficacy (namely the more recent phase III trials), and the 
QOL assessments already done would allow HIPEC to more quickly become a staple in 
the treatment of advanced ovarian cancer. 
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